AGMB
NASDAQAgomAb Therapeutics NV
News · 26 weeks31-71%
2025-12-142026-06-07
Mix2390d
- Insider11(48%)
- Other8(35%)
- SEC Filings3(13%)
- Offering1(4%)
Latest news
25 items- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - Agomab Therapeutics NV (0002020932) (Filer)
- PRAgomab Announces Results of Annual General MeetingAntwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026. All items on the agenda were approved, including: Approval of the statutory financial statements for the financial year ended December 31, 2025.Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.Reappointment of Mr. Ohad Hammer as a member of the Board of Directors for a term of one year.Rea
- SECSEC Form SCHEDULE 13G filed by AgomAb Therapeutics NVSCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)
- SECSEC Form SCHEDULE 13G filed by AgomAb Therapeutics NVSCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)
- PRAgomab to Participate in Upcoming ConferencesAntwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences: ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects' on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Fir
- SECSEC Form SCHEDULE 13G filed by AgomAb Therapeutics NVSCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)
- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - Agomab Therapeutics NV (0002020932) (Filer)
- PRAgomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease (FSCD) ---- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 ---- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Hal
- SECSEC Form 20-F filed by AgomAb Therapeutics NV20-F - Agomab Therapeutics NV (0002020932) (Filer)
- SECSEC Form SCHEDULE 13G filed by AgomAb Therapeutics NVSCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)
- PRAgomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary FibrosisAntwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company's investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This patent provides intellectual property (IP) protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions. "The issuance of th
- INSIDERSEC Form 3 filed by new insider Bond Colin Michael3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Van Der Horst Paul Henryk3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Knotnerus Tim Jasper3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Borderias Andrea Saez3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Verduyn-Van Weegen Felice Isabel3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Epstein David R3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lefever Ellen3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hammer Ohad3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kemula Pierre Thadee Victor3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wiesel Philippe Constantin3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jahreis Angelika Martha3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SECSEC Form S-8 filed by AgomAb Therapeutics NVS-8 - Agomab Therapeutics NV (0002020932) (Filer)
- SECSEC Form SCHEDULE 13G filed by AgomAb Therapeutics NVSCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)
- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - Agomab Therapeutics NV (0002020932) (Filer)
AGMB FAQ
6 questionsWhere does AGMB stock trade?
AgomAb Therapeutics NV (AGMB) is listed on NASDAQ.What sector and industry is AGMB in?
AgomAb Therapeutics NV operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did AgomAb Therapeutics NV go public?
AgomAb Therapeutics NV (AGMB) completed its IPO in 2026.What are analysts saying about AGMB?
AgomAb Therapeutics NV has had 3 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $3200.00 price target on 2026-03-03. Recent price targets range from $2800.00 to $3600.00.What companies are similar to AGMB?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AGMB side-by-side with any of them on Quantisnow.How can I track AGMB on Quantisnow?
Quantisnow aggregates AgomAb Therapeutics NV's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AGMB to receive live email and push alerts on every new disclosure.